Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome

Launched by KHYBER MEDICAL UNIVERSITY PESHAWAR · Apr 27, 2021

Keywords

ClinConnect Summary

Polycystic ovarian syndrome (PCOS) is extremely prevalent and considered to be the most common heterogeneous endocrine disorder in reproductive age women. This affects up to 10-15% of women in reproductive age. PCOS is a multifaceted health issue characterized by chronic anovulation with excess ovarian activity, hyperandrogenism and polycystic ovaries. The most disappointment for women with PCOS is pregnancy loss.

This endocrine disorder has some long term effects including cardiovascular diseases, metabolic and sexual dysfunction, depression and anxiety that effects the overall quality of...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Treatment naive PCOS women having age from 14-45 years with scanty or no menstruation, hirsutism and elevated serum androgen levels, will be diagnosed on the basis of AES (Androgen access society) guidelines 2006 according to which when two of the following criteria are present patient will be said to have the syndrome
• • 2. Hirsutism or hyperandrogenism
• • 3. Oligo or an-ovulation and or polycystic ovaries
• Exclusion Criteria:
• • 1. Women with previous history of Cushing syndrome
• • 2. Thyroid disorders
• • 3. Hyperprolactinemia
• • 4. Ovarian tumors
• • 5. Congenital adrenal hyperplasia androgen-producing tumors,
• • 6. History of seizures
• • 7. Patients on warfarin, Coumadin and Sintrom because of drug interaction with acetyl-L-Carnitine,
• • 8. Pregnancy or using contraceptive medications,
• • 9. Patients on hormonal therapy that alters the biochemical or hormonal profile